Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy‐Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy

BACKGROUND: NEPA, a combination antiemetic of a neurokinin‐1 (NK(1)) receptor antagonist (RA) (netupitant [oral]/fosnetupitant [intravenous; IV]) and 5‐HT(3)RA, palonosetron] offers 5‐day CINV prevention with a single dose. Fosnetupitant solution contains no allergenic excipients, surfactant, emulsi...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwartzberg, Lee, Navari, Rudolph, Clark‐Snow, Rebecca, Arkania, Ekaterine, Radyukova, Irena, Patel, Kamal, Voisin, Daniel, Rizzi, Giada, Wickham, Rita, Gralla, Richard J., Aapro, Matti, Roeland, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Symptom Management and Supportive Care
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066686/
https://www.ncbi.nlm.nih.gov/pubmed/32162813
http://dx.doi.org/10.1634/theoncologist.2019-0527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066686/
https://www.ncbi.nlm.nih.gov/pubmed/32162813
http://dx.doi.org/10.1634/theoncologist.2019-0527

Ejemplares similares